Novel quinoxaline inhibitors of pi3k

A compound of Formula I or a pharmaceutically acceptable salt thereof,

• wherein A is a monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;
• wherein A is optionally substituted with 1-3 substituents;
• X is selected from the group consisting of C(Rb)2, CH2CHRb, and CH═C(Rb);
• Y is selected from the group consisting of null, S, SO, SO2, NRd, O, C(═O), OC(═O), C(═O)O, and NHC(═O)CH2S;
• R1 and R2, independently, are selected from the group consisting of hydrogen, halo, NO2, CF3, OCF3, and CN, or from the group consisting of C1-6alkyl, aryl, heteroaryl, NHC(═O)C1-3alkyleneN(Ra)2, ORa, N(Ra)2, OC(═O)Ra, C(═O)Ra, C(═O)ORa, arylORa, Het, NRaC(═O)C1-3alkyleneC(═O)ORa, arylOC1-3alkyleneN(Ra)2, arylOC(═O)Ra, C1-4alkyleneC(═O)ORa, OC1-4alkyleneC(═O)ORa, C1-4alkyleneOC1-4alkyleneC(═O)ORa, C(═O)NRaSO2Ra, C1-4alkyleneN(Ra)2, C2-6alkenyleneN(Ra)2, C(═O)NRaC1-4alkyleneORa, C(═O)NRaC1-4alkyleneHet, OC2-4alkyleneN(Ra)2, OC1-4alkyleneCH(ORa)CH2N(Ra)2, OC1-4alkyleneHet, OC2-4alkyleneORa, OC2-4alkyleneNRaC(═O)ORa, NRaC1-4alkyleneN(Ra)2, NRaC(═O)Ra, NRaC(═O)N(Ra)2, N(SO2C1-4alkyl)2, NRa(SO2C1-4alkyl), SO2N(Ra)2, OSO2CF3, C1-3alkylenearyl, C1-4alkyleneHet, C1-6alkyleneORa, C1-3alkyleneN(Ra)2, C(═O)N(Ra)2, NHC(═O)C1-3alkylenearyl, C3-8cycloalkyl, C3-8heterocycloalkyl, arylOC1-3alkyleneN(Ra)2, arylOC(═O)Ra, NHC(═O)C1-3alkyleneC3-8heterocycloalkyl, NHC(═O)C1-3alkyleneHet, OC1-4alkyleneOC1-4alkyleneC(═O)ORa, C(═O)C1-4alkyleneHet, and NHC(═O)haloC1-6alkyl, each of which is optionally substituted;
• or R1 and R2 are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom selected from the group consisting of N, O, and S;
• R3 is hydrogen or is a member selected from the group consisting of C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C1-4alkylenecycloalkyl, C2-6alkenyl, C1-3alkylenearyl, arylC1-3alkyl, C(═O)Ra, aryl, heteroaryl, C(═O)ORa, C(═O)N(Ra)2, C(═S)N(Ra)2, SO2Ra, SO2N(Ra)2, S(═O)Ra, S(═O)N(Ra)2, C(═O)NRaC1-4alkyleneORa, C(═O)NRaC1-4alkyleneHet, C(═O)C1-4alkylenearyl, C(═O)C1-4alkyleneheteroaryl, and C1-4alkylenearyl, each of which is optionally substituted with 1-3 substitutents;
• each Ra is independently selected from hydrogen or from the group consisting of C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C1-3alkyleneN(Rc)2, aryl, arylC1-3alkyl, C1-3alkylenearyl, heteroaryl, heteroarylC1-3alkyl, and C1-3alkyleneheteroaryl, each of which is optionally substituted;
• or two Ra groups on the same atom or on adjacent atoms are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;
• each Rb is independently selected from the group consisting of hydrogen, halo and CN or from the group consisting of C1-6alkyl, C1-6haloalkyl, C(═O)Ra, C(═O)ORa, heteroC1-3alkyl, C1-3alkyleneheteroC1-3alkyl, arylheteroC1-3alkyl, aryl, heteroaryl, arylC1-3alkyl, heteroarylC1-3alkyl, C1-3alkylenearyl, and C1-3alkyleneheteroaryl, each of which is optionally substituted;
• or Rb and Rd can be taken together to form a 5-7 membered optionally substituted ring;
• each Rc is independently selected from hydrogen or from the group consisting of C1-6alkyl, C3-8cycloalkyl, aryl, and heteroaryl, each of which is optionally substituted;
• wherein Rd is H or C1-10acyl;
• or Rd and Rb, if X comprises Rb, can be taken together to form a 5-7 membered optionally substituted ring;
• and
• each Het is a 5- or 6-membered heterocyclic ring, wherein said heterocyclic ring is saturated, partially unsaturated or aromatic, and said heterocyclic ring contains at least one heteroatom selected from the group consisting of N, O, and S;
• wherein Het is optionally substituted with 1-3 substituents.